The workings of the gut microbiome have gained increasing interest in recent years through
the mounting evidence that the microbiota plays an influential role in human health and
disease. A principal focus of this research seeks to further understand the production of
metabolic by-products produced by bacteria resident in the gut, and the subsequent
interaction of these metabolites on host physiology and pathophysiology of disease. Gut
bacterial metabolites of interest are predominately formed via metabolic breakdown of
dietary compounds including choline and L-carnitine (trimethylamine N-oxide), amino acids
(phenol- and indole-containing uremic toxins) and non-digestible dietary fibers (short-chain
fatty acids). Investigations have been accelerated through the application of mass
spectrometry-based assays to quantitatively assess the concentration of these metabolites in
laboratory- and animal-based experiments, as well as for direct circulating measurements in
clinical research populations. This review seeks to explore the impact of these metabolites on
disease, as well as to introduce the application of mass spectrometry for those less
accustomed to its use as a clinical tool, highlighting pertinent research related to its use for
measurements of gut bacteria-mediated metabolites to further understand their associations
with disease.
This paper was published in the journal Clinical Chemistry and Laboratory Medicine and the definitive published version is available at https://doi.org/10.1515/cclm-2019-0974